Find a Tender
complete
Official procurement procedure
Chloraprep - Iskus
Medical equipments
pharmaceuticals and personal care products
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: BELFAST HEALTH AND SOCIAL CARE TRUST: "Chloraprep - Iskus". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | BELFAST HEALTH AND SOCIAL CARE TRUST | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: BELFAST HEALTH AND SOCIAL CARE TRUST
Market Analytics
Derived from OCDS awards & bid statistics
Published history for BELFAST HEALTH AND SOCIAL CARE TRUST. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
1Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 240 active published awards; 229 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityBELFAST HEALTH AND SOCIAL CARE TRUST | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published12 Feb 2021, 15:43 GMT | Last source update12 Feb 2021, 15:43 GMT | Recurring procurementNot published |
ClassificationMedical equipments, pharmaceuticals and personal care products | ||
Delivery area | ||
OCIDocds-h6vhtk-0292df | ||
What is being bought
Chloraprep - Iskus
What changed
From the official release history
- Status changed to complete
12 Feb 2021, 15:43 GMT - Official notice release published
12 Feb 2021, 15:43 GMT - Buyer information updated
12 Feb 2021, 15:43 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedChloraprep - IskusContract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
12 Feb 2021, 15:43 GMT - Award active
Not published · Not published - Contract active
Signed 3 Feb 2021, 00:00 GMT · £150,000
Commercial outcome and competition
Awards Iskus Health Not published · Not published · active |
Contracts Chloraprep - Iskus £150,000 · signed 3 Feb 2021, 00:00 GMT · active |
Bid statistics bids: 1 (lot 1) |
Buyer and organisations in this procedure
BELFAST HEALTH AND SOCIAL CARE TRUST
Contracting authority GB-FTS-4486Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleChloraPrep is a rapid-acting, persistent, and broad-spectrum antiseptic for a range of major medical procedures. The 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol formulation acts fast on a broad spectrum of bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA The formulation supports Trust infection control guidelines for helping to reduce the incidence of blood stream infections (BSI) and surgical site infections (SSI). This is a branded patent protected medicine |